ASP3026
Description:
Target: ALK
IC50: 3.5 nM
ASP3026 is a novel, selective and oral small molecule ALK inhibitor with IC50 value of 3.5 nM [1]. ALK plays important roles in the development and survival of ALK+ tumors including non-small cell lung cancer (NSCLC), inflammatory myofibroblastic tumor, neuroblastoma, and NPM-ALK+ T-cell anaplastic large-cell lymphoma. Therefore, targeting ALK is a promising strategy for treating ALK+ tumors patients [2].
In vitro: ASP3026 (0.5, 1.5, and 2.5 μM) inhibited the proliferation, viability, and colony formation, as well as induced apoptotic cell death of NPM-ALK+ T-cells in a concentration-dependent manner via inhibiting NPM-ALK tyrosine kinase activity [2].
In vivo: ASP3026 (30 mg/kg, daily oral
Description:
Target: ALK
IC50: 3.5 nM
ASP3026 is a novel, selective and oral small molecule ALK inhibitor with IC50 value of 3.5 nM [1]. ALK plays important roles in the development and survival of ALK+ tumors including non-small cell lung cancer (NSCLC), inflammatory myofibroblastic tumor, neuroblastoma, and NPM-ALK+ T-cell anaplastic large-cell lymphoma. Therefore, targeting ALK is a promising strategy for treating ALK+ tumors patients [2].
In vitro: ASP3026 (0.5, 1.5, and 2.5 μM) inhibited the proliferation, viability, and colony formation, as well as induced apoptotic cell death of NPM-ALK+ T-cells in a concentration-dependent manner via inhibiting NPM-ALK tyrosine kinase activity [2].
In vivo: ASP3026 (30 mg/kg, daily oral